Masha Zhdanava
Education
M.A., economics, Dalhousie University; B.A., economics, European Humanities University
Summary of Experience
Ms. Zhdanava specializes in the application of statistical methods to the field of health economics and outcomes research. Her expertise includes burden of illness analyses, treatment effectiveness and treatment patterns analyses, disease epidemiology studies, and cost models. Ms. Zhdanava has worked with a variety of data, including health insurance claims, electronic medical records, and data collected from chart reviews. Her research in a wide range of therapeutic areas, including depression, schizophrenia, asthma, psoriasis, and oncology, has been presented at conferences and published in peer-reviewed journals such as the Journal of Clinical Psychiatry, the Journal of Affective Disorders, BMC Psychiatry, Allergy & Asthma Proceedings, Clinical Therapeutics, Current Medical Research and Opinion, and the Journal of Medical Economics.
- 
                                                        Real-World Maintenance Phase Persistence on Ustekinumab and Adalimumab in Ulcerative ColitisPatient Preference and Adherence, 2024 
 2024Zhdanava M, Kachroo S, Shah A, Ding Z, Lefebvre P, Zhao R, Kerner C, Pilon D 
- 
                                                        Burden of chronic corticosteroid use among patients with ulcerative colitis initiated on targeted treatment or conventional therapy in the United StatesJournal of Managed Care & Specialty Pharmacy, 2024 
 2024Zhdanava M, Zhao R, Manceur AM, Ding Z, Boudreau J, Kachroo S, Kerner C, Izanec J, Pilon D 
- 
                                                        Understanding profiles of patients with treatment-resistant depression by stringency of health plan prior authorization criteria for approval of esketamine nasal sprayCurrent Medical Research and Opinion, 2024 
 2024Harding L, Zhdanava M, Shah A, Pesa J, Totev TI, Tardif-Samson A, Pilon D, Joshi K 
- 
                                                        Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United StatesDrugs - Real World Outcomes, 2024 
 2024Harding L, Joshi K, Zhdanava M, Shah A, Voegel A, Chen C, Pilon D 
- 
                                                        Predictors of High Healthcare Cost Among Patients with Generalized Myasthenia Gravis: A Combined Machine Learning and Regression Approach from a US Payer PerspectiveApplied Health Economics and Health Policy, 2024 
 2024Zhdanava M, Pesa J, Boonmak P, Schwartzbein S, Cai Q, Pilon D, Choudhry Z, Lafeuille MH, Lefebvre P, Souayah N 
- 
                                                        Comparison of real-world healthcare resource utilization among advanced therapy-naïve and advanced therapy-experienced patients with ulcerative colitis initiated on ustekinumab or vedolizumabCurrent Medical Research and Opinion, 2024 
 2024Zhdanava M, Kachroo S, Boonmak P, Burbage S, Shah A, Korsiak J, Patrick Lefebvre P, Kerner C, Pilon D 
- 
                                                        Real-World Long-Term Persistence and Surgical Procedure-Free Period Among Bio-naïve Patients with Crohn's Disease and Fistula Initiated on UstekinumabAdvances in Therapy, 2024 
 2024Zhdanava M, Kachroo S, Boonmak P, Burbage S, Shah A, Lefebvre P, Kerner C, Pilon D 
- 
                                                        Real-World Treatment Persistence Among Advanced Therapy-Naïve or -Experienced Patients with Ulcerative Colitis Initiated on Ustekinumab or AdalimumabAdvances in Therapy, 2024 
 2024Zhdanava M, Kachroo S, Boonmak P, Burbage S, Shah A, Korsiak J, Lefebvre P, Kerner C, Pilon D 
- 
                                                        Economic Burden Associated With Nasal Polyposis Recurrence Among Commercially Insured Patients in the United StatesOtolaryngology–Head and Neck Surgery, 2023 
 2023Zhdanava M, Ndife B, Pilon D, Rossi C, Vermette-Laforme M, Lefebvre P, Suh JD 
- 
                                                        Ischemic Stroke and Systemic Embolism among One-and-Done Direct Oral Anticoagulant Users with Non-Valvular Atrial FibrillationAdvances in Therapy, 2023 
 2023Alberts M, Zhdanava M, Pilon D, Caron-Lapointe G, Lefebvre P, Bookhart B, Kharat A 
- 
                                                        Treatment Patterns, Healthcare Utilization, and Costs of Patients with Treatment-Resistant Depression Initiated on Esketamine Intranasal Spray and Covered by Us Commercial Health PlansJournal of Medical Economics, 2023 
 2023Joshi K, Pilon D, Shah A, Holiday C, Karkare S, Zhdanava M 
- 
                                                        Venous Thromboembolism Recurrence among One-and-Done Direct Oral Anticoagulant Users: A Retrospective Longitudinal StudyInternational Journal of Clinical Pharmacy, 2023 
 2023Alberts M, Zhdanava M, Pilon D, Caron-Lapointe G, Lefebvre P, Bookhart B, Kharat A 
- 
                                                        Esketamine Nasal Spray for Major Depressive Disorder with Acute Suicidal Ideation or Behavior: Description of Treatment Access, Utilization, and Claims-Based Outcomes in the United StatesJournal of Medical Economics, 2023 
 2023Zhdanava M, Teeple A, Pilon D, Shah A, Caron-Lapointe G, Joshi K 
- 
                                                        Treatment Persistence among Bio-Naïve Patients with Crohn's Disease Initiated on Ustekinumab or AdalimumabCurrent Medical Research and Opinion, 2023 
 2023Zhdanava M, Ding Z, Manceur AM, Muser E, Lefebvre P, Holiday C, Lafeuille MH, Pilon D 
- 
                                                        Long-term persistence and other treatment patterns among bio-naïve patients with Crohn's disease treated with ustekinumab or adalimumabCurrent Medical Research and Opinion, 2023 
 2023Zhdanava M, Ding Z, Manceur AM, Zhao R, Holiday C, Kachroo S, Izanec J, Pilon D 
- 
                                                        Persistence and Dose Escalation During Maintenance Phase and Use of Nonbiologic Medications Among Patients With Ulcerative Colitis Initiated on Ustekinumab in the United StatesCrohn's & Colitis 360, 2023 
 2023Zhdanava M, Zhao R, Manceur AM, Kachroo S, Lefebvre P, Pilon D 
- 
                                                        Ischemic stroke and systemic embolism among patients with non-valvular atrial fibrillation who abandon oral anticoagulant therapyCurrent Medical Research and Opinion, 2023 
 2023Alberts MJ, Zhdanava M, Pilon D, Caron-Lapointe G, Lefebvre P, Bookhart B, Kharat A 
- 
                                                        Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insuranceCurrent Medical Research and Opinion, 2023 
 2023Teeple A, Zhdanava M, Pilon D, Caron-Lapointe G, Lefebvre P, Joshi K 
- 
                                                        Persistence and other treatment patterns among bio-experienced patients with Crohn's disease initiated on ustekinumab or adalimumabJournal of Managed Care & Specialty Pharmacy, 2023 
 2023Zhdanava M, Zhao R, Manceur AM, Ding Z, Kachroo S, Holiday C, Lefebvre P, Pilon D 
- 
                                                        Persistence Among Patients with Crohn Disease Previously Treated with an Anti-tumor Necrosis Factor Inhibitor and Switching or Cycling to Another Biologic AgentClinical Therapeutics, 2023 
 2023Zhdanava M, Kachroo S, Manceur AM, Ding Z, Holiday C, Zhao R, Godwin B, Pilon D 
- 
                                                        Chronic corticosteroid use is associated with substantial clinical and economic burden in patients with Crohn's Disease initiated on biologic or conventional therapies in the US: A retrospective studyJournal of American Pharmacists Association, 2023 
 2023Zhdanava M, Zhao R, Manceur AM, Ding Z, Boudreau J, Kachroo S, Kerner C, Izanec J, Pilon D 
- 
                                                        Economic Burden of Commercially Insured Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior in the United StatesJournal of Clinical Psychiatry, 2022 
 2022Pilon D, Neslusan C, Zhdanava M, Sheehan J, Joshi K, Morrison L, Rossi C, Lefebvre P, Greenberg P 
- 
                                                        Characteristics of Real-World Commercially Insured Patients With Treatment-Resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United StatesClinical Therapeutics, 2022 
 2022Karkare S, Zhdanava M, Pilon D, Nash AI, Morrison L, Shah A, Lefebvre P, Joshi K 
- 
                                                        Understanding the Health System Conditions Affecting the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia in Clinical Practice: A US Healthcare Provider SurveyNeuropsychiatric Disease and Treatment, 2022 
 2022Zhdanava M, Starr HL, Lefebvre P, Totev TI, Shah A, Sheng K, Pilon D 
- 
                                                        Excess healthcare resource utilization and healthcare costs among privately and publicly insured patients with major depressive disorder and acute suicidal ideation or behavior in the United StatesJournal of Affective Disorders, 2022 
 2022Zhdanava M, Voelker J, Pilon D, Joshi K, Morrison L, Sheehan JJ, Vermette-Laforme M, Lefebvre P, Citrome L 
- 
                                                        Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USAPharmacoEconomics (2021) 39:707–720 
 2021Zhdanava M, Voelker J, Pilon D, Cornwall T, Morrison L, Vermette‑Laforme M, Lefebvre P, Nash A, Joshi K, Neslusan C 
- 
                                                        The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United StatesJournal of Clinical Psychiatry, 2021 
 2021Zhdanava M, Pilon D, Ghelerter I, Chow W, Joshi K, Lefebvre P, Sheehan JJ 
- 
                                                        Special Issue of PharmacoEconomics on Major Depressive DisordersPharmacoEconomics (2021) 39:617 
 2021
- 
                                                        Prevalence of Pre-existing Conditions Relevant for Adverse Events and Potential Drug-Drug Interactions Associated with Augmentation Therapies Among Patients with Treatment-Resistant DepressionAdvances in Therapy, 2021 
 2021Zhdanava M, Karkare S, Pilon D, Joshi K, Rossi C, Morrison L, Sheehan J, Lefebvre P, Lopena O, Citrome L 
- 
                                                        Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychoticsJournal of Managed Care & Specialty Pharmacy, 2021 
 2021Pilon D, Patel C, Lafeuille MH, Zhdanava M, Lin D, Côté-Sergent A, Rossi C, Lefebvre P, Joshi K 
- 
                                                        Prevalence, incidence and economic burden of schizophrenia among Medicaid beneficiariesCurrent Medical Research and Opinion, 2021 
 2021Pilon D, Patel C, Lafeuille MH, Zhdanava M, Lin D, Côté-Sergent A, Rossi C, Joshi K, Lefebvre P 
- 
                                                        Health care resource use, short-term disability days, and costs associated with states of persistence on antidepressant lines of therapyJournal of Medical Economics, 2021 
 2021Pilon D, Karkare S, Zhdanava M, Sheehan JJ, Côté-Sergent A, Shah A, Lopena OJ, Lefebvre P, Joshi K, Citrome L 
- 
                                                        Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorderCurrent Medical Research and Opinion, 2021 
 2021Zhdanava M, Kuvadia H, Joshi K, Daly E, Pilon D, Rossi C, Morrison L, Lefebvre P, Nelson C 
- 
                                                        Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical ConditionsJournal of Managed Care & Specialty Pharmacy, 2020 
 2020Zhdanava M, Kuvadia H, Joshi K, Daly E, Pilon D, Rossi C, Morrison L, Lefebvre P, Nelson C 
- 
                                                        Prevalence of Potential Drug-Drug Interactions and Pre-existing Conditions for Adverse Events in Augmentation Therapies Among Patients With Treatment-resistant DepressionPsych Congress, 2020 
 2020Zhdanava M, Karkare S, Pilon D, Joshi K, Rossi C, Morrison L, Sheehan J, Lefebvre P, Lopena O, Citrome L 
- 
                                                        Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plansCurrent Medical Research and Opinion, January 5, 2019 
 2019Emond B, El Khoury AC, Patel C, Pilon D, Morrison L, Zhdanava M, Lefebvre P, Tandon N, Joshi K 
- 
                                                        Is clinician impression of depression symptom severity associated with incremental economic burden in privately insured US patients with treatment resistant depression?Journal of Affective Disorders, 2019 
 2019Pilon D, Sheehan JJ, Szukis H, Morrison L, Zhdanava M, Lefebvre P, Joshi K 
- 
                                                    October 23, 2023
- 
                                                    March 2, 2023
- 
                                                    April 12, 2022
- 
                                                    June 14, 2021
- 
                                                    June 10, 2021
- 
                                                    June 8, 2021
- 
                                                    January 21, 2021
